Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Orchard Therapeutics

Request full access

Hematopoietic stem cell gene therapies for rare diseases

London, United KingdomFounded 2015Biotech & Life Sciences

About Orchard Therapeutics

Orchard Therapeutics, a subsidiary of Kyowa Kirin, is a global pharmaceutical company developing and commercializing potentially curative, one-time gene therapies for patients with severe and life-threatening rare diseases. The company was founded in 2015 as a spin-out from University College London (UCL), based on the research of scientific founders Professors Bobby Gaspar and Adrian Thrasher at the UCL Great Ormond Street Institute of Child Health. Dr. Gaspar, who now serves as CEO, was motivated by his work as a pediatric immunologist, seeking a safer and more effective alternative to bone marrow transplants for children with severe immune deficiencies. This led to pioneering the use of a patient's own genetically modified hematopoietic stem cells (HSCs) to correct the underlying cause of a disease.

The company's approach involves extracting a patient's blood stem cells, modifying them genetically outside the body (ex vivo) to insert a functional copy of a faulty gene, and then reinfusing them into the patient. This autologous method aims to provide a single, transformative treatment. Orchard's business model centers on the development and commercialization of these high-value therapies. Revenue is generated from the sale of its approved products. In January 2024, Orchard was acquired by Kyowa Kirin, a Japan-based global specialty pharmaceutical company, for approximately $477.6 million, to enhance Kyowa Kirin's pipeline and focus on rare diseases.

Orchard's leading product, marketed as Libmeldy® in Europe and Lenmeldy™ in the U.S., is an approved treatment for early-onset metachromatic leukodystrophy (MLD), a rare and fatal metabolic disorder. Libmeldy received approval from the European Medicines Agency (EMA) in 2020 and the U.S. Food and Drug Administration (FDA) in 2024. The company's clinical-stage pipeline includes therapies for other rare genetic disorders, such as OTL-203 for mucopolysaccharidosis type I Hurler's syndrome (MPS-IH) and OTL-201 for mucopolysaccharidosis type IIIA (MPS-IIIA). The company has also advanced programs for Wiskott-Aldrich syndrome (WAS) and adenosine deaminase severe combined immunodeficiency (ADA-SCID).

Source: Dealroom company data

At a glance

Status
Listed
Listing
IPO 2018

Orchard Therapeutics in the London ecosystem

Live from Dealroom

The Orchard Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

26 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • California Institute for Regenerative Medicine

Series A12 investors entered at this stage

  • F-Prime
  • Baillie Gifford
  • ORI Capital
  • Temasek
  • Cowen Group
  • Juda Capital
  • AlbionVC
  • Pavilion Capital Partners
  • Agent Capital
  • 4BIO Capital
  • UCL Technology Fund
  • RTW Investments

Series B and later13 investors entered at this stage

Employees mapped 243 incl. 1 AI specialist
Founders Hidden — book a demo/100 quality score
Key operators 19 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Patents

Estimated portfolio value
$383k

6 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

See Orchard Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.